Navigation Links
CuraGen Announces Presentation of Phase I Dose-Escalation Results on CR011- vcMMAE for Metastatic Melanoma
Date:10/24/2007

- Initial clinical trial results suggesting safety and clinical activity of CR011-vcMMAE reported at the AACR-NCI-EORTC International Conference -

BRANFORD, Conn., Oct. 24 /PRNewswire-FirstCall/ -- CuraGen Corporation (Nasdaq: CRGN), a clinical-stage biopharmaceutical company focused on oncology, announced that the first Phase I clinical trial results on CR011- vcMMAE, an antibody-drug conjugate (ADC) being developed for the treatment of metastatic melanoma, were presented today at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in San Francisco, CA. To date, 25 patients with unresectable Stage III or IV malignant melanoma have been treated with CR011-vcMMAE in the Phase I dose-escalation portion of the trial.

Results from the ongoing trial suggest the CR011-vcMMAE is well-tolerated at doses up through 1.88 mg/kg with no dose-limiting toxicities noted. Dose- escalation continues with patients currently being enrolled into the 2.63 mg/kg cohort. Of the 25 patients treated with doses ranging from 0.03 mg/kg to 1.88 mg/kg, six patients achieved stable disease lasting up to 11 cycles, and four of the six patients demonstrated tumor shrinkage of up to 20%. Reversible neutropenia was the only drug-related Grade 3 or 4 adverse event, and appears to be dose-dependent. Evaluation of the pharmacokinetic results also suggest that CR011-vcMMAE can be given safely to achieve human plasma concentrations in the anticipated range of activity based on data from in vivo xenograft animal models.

Upon establishing the maximum tolerated dose (MTD), the trial is expected to expand directly into a Phase II study to further assess the activity of CR011-vcMMAE in up to 32 patients wit
'/>"/>

SOURCE CuraGen Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. CuraGen Presents Update on Clinical Development Program for Belinostat
2. CuraGen and TopoTarget Announce New Clinical Results With Belinostat to be Reported at Upcoming Major Medical Meetings
3. CuraGen Announces New Preclinical Results with Belinostat and Velafermin to be Presented at AACR Annual Meeting
4. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
5. Sygnis Pharma AG announces date for presentation of clinical results
6. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
8. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
9. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
10. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... , Aug. 28, 2015 ... the addition of the "Investigation Report on ... their offering. Developed by Novo Nordisk, ... is an important drug for the treatment of ... a fast- acting insulin analog, starts working fast ...
(Date:8/28/2015)... 2015 Research and Markets ... "Investigation Report on China,s Ranibizumab Market, 2012-2019" ... ranibizumab was approved by CFDA to treat wet age- ... a product of Novartis, is available in the Chinese ... developed drug for the treatment of wet AMD in ...
(Date:8/28/2015)... PRINCETON, N.J. , Aug. 28, 2015  IP Shakti, ... Prediqtus, LLC. ... "Our new corporate identity signifies our ... the world,s first predictive analytics platform for patent claim validity." ... with the launch of the proprietary AIA Shield™ platform, the ...
Breaking Medicine Technology:China Insulin Aspart Market Report 2010-2019 - Developed by Novo Nordisk 2Investigation Report on China's Ranibizumab Market, 2012-2019 2IP Shakti, LLC Changes Company Name to Prediqtus, LLC 2
(Date:8/30/2015)... ... 2015 , ... The law firm of Tomasik Kotin ... recently elected to membership in the American Board of Trial Advocates (ABOTA). ... outstanding professionalism. , ABOTA is an invitation-only, national organization comprised of judges ...
(Date:8/30/2015)... (PRWEB) , ... August 30, 2015 , ... Natural Rest ... beneficial effects as sleep aids and calming remedies, which help to improve mood disorders ... of a great deal of research in the field of regenerative medicine conducted by ...
(Date:8/29/2015)... ... ... Rio Salado College President Chris Bustamante announced on Aug. 19 ... Initiatives and Information Services. O’Shea, who has served Rio Salado for the last two ... through innovative technologies and strategies. , “I am very proud to be able to ...
(Date:8/29/2015)... PA (PRWEB) , ... August 29, 2015 , ... ... due to insufficient scrotal support and protection against dribbled urine and sweat. "In ... from Manhasset Hills, N.Y. , The EASY ACCESS DRYNESS ENHANCED MEN'S UNDERGARMENT provides ...
(Date:8/29/2015)... , ... August 29, 2015 , ... ProDrop Particles includes ... Each preset contains 15 seconds of unique footage that users can shrink and stretch ... zoom, attract and more. Users can customize color, brightness, scale, speed, range, and flare ...
Breaking Medicine News(10 mins):Health News:Chicago Personal Injury Lawyer Daniel M. Kotin Elected to the American Board of Trial Advocates 2Health News:Chicago Personal Injury Lawyer Daniel M. Kotin Elected to the American Board of Trial Advocates 3Health News:Creative Medical Health’s Natural Rest® Now Available on ReCreative Medical Health’s Natural Rest® Now Available on RevNutrition.com 2Health News:Rio Salado College Appoints New Vice President of Strategic Initiatives and Information Services 2Health News:Modified Men’s Underwear Promote More Comfort and Hygiene - Designed by InventHelp Client (LGI-1968) 2Health News:FCPX Effects Developer, Pixel Film Studios, Releases ProDrop Particles. 2
... THURSDAY, Feb. 23 (HealthDay News) -- Children with ... attention-deficit hyperactivity disorder (ADHD) and other related disorders, but ... Researchers analyzed data from more than 1,000 U.S. teens ... of psychiatric medications in those with autism, ADHD and ...
... Reinberg HealthDay Reporter , THURSDAY, Feb. 23 (HealthDay ... but this winter,s flu season is finally here, say experts ... They report that flu activity picked up in the past ... influenza season since 1987-1988. Lab-confirmed cases of influenza have now ...
... CINCINNATI Scientists have developed a unique compound ... blood cells known to fuel ailments like cancer ... Past attempts to identify new compounds ... molecules in cells have been complicated by toxicity ...
... WEDNESDAY, Feb. 22 (HealthDay News) -- Melanoma that has spread ... but a new drug appears to double survival for those ... A mutation in the BRAF protein occurs in about ... a drug approved by the U.S. Food and Drug Administration ...
... Feb. 23 (HealthDay News) -- The first molecular evidence linking ... death could lead to new methods of diagnosis and therapy ... study suggests. Abnormal heart rhythms called ventricular arrhythmias are ... the primary cause of death from heart disease. Experts have ...
... HealthDay Reporter , THURSDAY, Feb. 23 (HealthDay News) -- ... might just be the beginning of your spring allergies ... had warmer-than-average winter weather, which is causing trees to ... Stanley Fineman, president of the American College of Allergy, ...
Cached Medicine News:Health News:Meds for Autism Not Well Understood: Study 2Health News:Flu Season Off to a Very Late Start: CDC 2Health News:New class of compounds stops disease-fueling inflammation in lab tests 2Health News:New class of compounds stops disease-fueling inflammation in lab tests 3Health News:New Melanoma Drug May Extend Survival 2Health News:New Melanoma Drug May Extend Survival 3Health News:Study Links 'Body Clock' to Sudden Cardiac Death 2Health News:Mild Winter Heralds Early Sneezin' Season 2Health News:Mild Winter Heralds Early Sneezin' Season 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: